Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
NEW YORK, May 01, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.
Intercept management will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
- Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
- UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
- Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
